RAC 0.57% $1.75 race oncology ltd

IMO. DYOR. Not advice. There has been some discussion of LAG-3...

  1. 11,249 Posts.
    lightbulb Created with Sketch. 29637
    IMO. DYOR. Not advice.

    There has been some discussion of LAG-3 today via Post #:60855711 from @Lymphnode63.

    USD $4B peak sales estimates for Opdualag from the below:

    https://www.fiercepharma.com/pharma...scores-fda-approval-melanoma-opens-3rd-immune

    At weighted average 4.5x ( from Post #:60252701 ) x USD $4B peak sales implies the drug be worth up to USD $18B in a transaction using metrics derived from buyouts of drugs.

    From below Opdualag will cost USD $27,389 per infusion.

    https://endpts.com/fda-oks-bristol-...new-class-of-checkpoint-inhibitor-in-8-years/

    Contrast this with the cosy of USD $6,580 for Opdivo alone:

    https://www.healthline.com/health/medicare/does-medicare-cover-opdivo#cost

    US $27,389 (Opdualag combination) - US $6,580 ( Opdivo alone ) = USD $20,809

    So the LAG-3 inhibitor is 76% of the price of the anti-PD1 + anti-LAG3 combination. This perhaps gives an indicative value per infusion USD $20,809 of Zantrene in combination with an anti-PD1.

    It will be interesting to see what any research house valuation comes up with.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.75
Change
0.010(0.57%)
Mkt cap ! $298.0M
Open High Low Value Volume
$1.73 $1.83 $1.73 $272.0K 152.3K

Buyers (Bids)

No. Vol. Price($)
1 9998 $1.75
 

Sellers (Offers)

Price($) Vol. No.
$1.79 2000 1
View Market Depth
Last trade - 16.10pm 09/07/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.